Stage i non-small cell lung cancer: The presence of the lymphocytespecific protein tyrosin kinase in the tumour infiltrate is associated with a better long-term prognosis

Interactive Cardiovascular and Thoracic Surgery

Volumn 15, Issue 1, 2012, Pages 148-151

  D'Andrillia, Antonio ^a   Natolib, Guido ^a   Scarpinoc, Stefania ^a   Rendina, Erino A ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Fondazione Eleonora Lorillard Spencer Cenci   (Italy)

Author keywords

Lymphocyte specific protein tyrosine kinase; Non small cell lung cancer

Indexed keywords

PROTEIN KINASE LCK;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPHADENECTOMY; MALE; MEDIASTINUM LYMPH NODE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PNEUMONECTOMY; RETROSPECTIVE STUDIES; ROME; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863434078     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivr128     Document Type: Article

References (10)

1. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71.
2. Chen H-Y, Yu S-L, Chen C-H, Chang G-C, Chen C-Y, Yuan A et al. A fivegene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007;356:11-20.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3: 991-8.
4. Naito M, Komohara Y, Ishihara Y, Noguchi M, Yamashita Y, Shirakusa T et al. Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles. Br J Cancer 2007;97:1648-54.
5. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009;27:1746-52.
6. Capurso G, Lattimore S, Jurcevic T, Panzuto F, Milione M, Bhakta V et al. Gene expression profiles of progressive endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer 2006;13:541-58.
7. Kim R, Emi M, Tanabe K, Arihiro K. Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66: 5527-36.
8. Thomas SM, Brugge JS. Cellular functions regulated by Src familiy kinases. Annu Rev Cell Dev Biol 1997;13:513-609.
9. Masaki T, Igarashi K, Tokuda M, Yukimasa S, Han F, Jin YJ et al. pp60 src activation in lung adenocarcinoma. Eur J Cancer 2003;39:1447-55.
10. Meireles SJ, Cristo EB, Carvalho AF, Hirata R Jr, Pelosof A, Gomes LI et al. Mocelular classifiers for gastric cancer and non malignant diseases of gastric mucosa. Cancer Res 2004;64:1255-65.